Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

221
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

185
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma

Pages

  631-641

Abstract

 Iguratimod is a new synthetic disease-modifying antirheumatic drug intended to treat patients with rheumatoid arthritis. A new method using Recombinant human CYP450s yeast cells containing c-DNA expressed P450s was applied to identify the Metabolic pathways of Iguratimod and to prepare its metabolite. The metabolite was isolated, and its structure was identified by quadrupole time-of-flight-mass spectrometry and nuclear magnetic resonance. Furthermore, a selective and sensitive high performance liquid chromatography (HPLC) method was developed for the simultaneous quantification of Iguratimod and its major metabolite in rat plasma for the first time. The results indicated that Iguratimod was mainly metabolized to a metabolite by CYP2C9 and CYP2C19 in in-vitro study. The structure of the metabolite was identified as M2 (N-[3-(acetamido)-4-oxo-6-phenoxy-4H-chromen-7-yl] methanesulfonamide). HPLC assay was achieved on a C18 column using methanol-water containing 0. 1% trifluoroacetic acid (55: 45 v/v) at a flow rate of 1 mL/min with UV detection at 257 nm. Standard calibration curves were obtained in the concentration range of 0. 5– 20 μ g/mL for Iguratimod and its metabolite M2. The lower limits of detection of Iguratimod and M2 in rat plasma were 0. 1 and 0. 25 μ g/mL, respectively. The intra-and inter-day precision (RSD%) were within 5% for the two analytes. The average recoveries of the analytes were greater than 90%. In conclusion, Recombinant human CYP450s whole-yeast transformation system could be successfully used to identify and prepare the major metabolite of Iguratimod. The HPLC method we developed could be successfully applied to evaluate Pharmacokinetics of Iguratimod and its metabolite M2 in rats.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    Zhu, Zhen han, Wu, Yue zhang, Qian, Wen, Li, Zhi yu, Nishikawa, Miyu, & Sakaki, Toshiyuki. (2019). Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 18(2), 631-641. SID. https://sid.ir/paper/289118/en

    Vancouver: Copy

    Zhu Zhen han, Wu Yue zhang, Qian Wen, Li Zhi yu, Nishikawa Miyu, Sakaki Toshiyuki. Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2019;18(2):631-641. Available from: https://sid.ir/paper/289118/en

    IEEE: Copy

    Zhen han Zhu, Yue zhang Wu, Wen Qian, Zhi yu Li, Miyu Nishikawa, and Toshiyuki Sakaki, “Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 18, no. 2, pp. 631–641, 2019, [Online]. Available: https://sid.ir/paper/289118/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top